Recent 8-K filings for DGX

• April 21, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Quest Diagnostics Q1 revenue $2.90B (+9.2%), raises FY2026 EPS and revenue guidance

  Reported diluted EPS $2.24 (+15.5%); adjusted diluted EPS $2.50 (+13.1%).

• February 10, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01

  Quest Diagnostics Q4 rev $2.81B (+7.1%), adj EPS $2.42 (+8.5%); raises dividend 7.5%

  FY2025 revenue $11.04B (+11.8%), reported EPS $8.75 (+13.8%), adjusted EPS $9.85 (+10.3%).

• October 21, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84

  Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.

• July 22, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Quest Diagnostics Q2 revenues $2.76B (+15.2%), beats; raises FY2025 adjusted EPS guidance to $9.63-$9.83

  Q2 revenue $2.76B, up 15.2% YoY; organic revenue growth 5.2%.

• April 22, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Quest Diagnostics Q1 revenue up 12.1% to $2.65B, raises FY reported EPS guidance

  Q1 net revenues $2.65B (+12.1% YoY); reported diluted EPS $1.94 (+12.8%), adjusted diluted EPS $2.21 (+8.3%).

• January 30, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01

  Quest Diagnostics Q4 revenue $2.62B (+14.5%), adjusted EPS $2.23 (+3.7%); raises dividend 6.7% to $0.80

  Q4 revenue $2.62B (+14.5% YoY); reported diluted EPS $1.95 (+14.7%); adjusted diluted EPS $2.23 (+3.7%).

• October 22, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Quest Diagnostics Q3 revenue +8.5% to $2.49B, raises FY revenue guidance

  Q3 revenue $2.49B (+8.5% YoY); reported EPS $1.99 (+1.5%); adjusted EPS $2.30 (+3.6%).

• August 19, 2024, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 5.03item 8.01item 9.01

  Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition

  Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.

• July 23, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Quest Diagnostics beats Q2 estimates, raises full-year guidance; announces four acquisitions

  Q2 revenues $2.397B (+2.5% YoY); reported EPS $2.03 (-1% YoY), adjusted EPS $2.35 (+2.2% YoY)

• July 3, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 7.01item 9.01

  Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35B (~US$985M)

  Cash purchase price of ~C$1.35B (US$985M) including net debt, funded with cash and debt.

• April 23, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Quest Diagnostics Q1 revenue $2.37B (+1.5% YoY); raises full-year adjusted EPS to $8.72-$8.97

  Revenue $2.366B, up 1.5% YoY; base business revenue grew nearly 6%.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.62 · Most common event earnings

10 positive 0 negative 12 neutral

source · DGX on sec.gov